HHS Secretary Search: Alex Azar Checks The Most Important Box
Executive Summary
Former HHS No. 2 would bring extensive knowledge of the sprawling department and policy expertise in the drug pricing area, where the Trump Administration is readying new actions.
You may also be interested in...
Azar Tapped: Stakeholders Heap Praise On Trump HHS Nominee
The administration's nominee to head HHS is being praised by medtech health-care industry lobbyists but may experience some pushback in the Senate because of his ties to Eli Lilly.
US Medicare Plans 'Can' Cover Wegovy, CMS Says, But Will They?
Medicare is making clear that Part D ‘can’ cover GLP-1 inhibitors that are approved for cardiovascular indications – but in language that seems to leave plans considerable discretion for now. The formulary review process for 2025 may be a more important milestone for changes.
An Artificial Intelligence Milestone For US FDA
A project to validate a depression severity measurement tool that employs artificial intelligence for use in drug trials is moving forward at FDA. The milestone is a sign of things to come – and of the incremental process for AI adoption by the regulator.